Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1751 participants.
Also called NCT02648347
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,751 participants
- Sponsor
- Registry
-
NCT02648347 -
2015-004265-81
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Brazil, Bulgaria, France, Hungary, Israel, Italy, Malaysia, Mexico, New Zealand, Poland, Puerto Rico, Russia, South Africa, South Korea, Spain, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02648347. Randomized; no masking; primary purpose treatment. Start 2015-12 (actual); primary completion 2020-06-04 (actual). Results posted on 2022-06-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease
- Condition
- Anemia
- Condition
- Non-Dialysis-Dependent Chronic Kidney Disease
- Intervention (Drug)
- Vadadustat
- Intervention (Drug)
- Darbepoetin alfa
- Lead sponsor
- Akebia Therapeutics
Record details
- Record id
cardio:ct-nct02648347- Content hash
82998a789f3521ff12ca0c1602d707e5e1743ba7fa873d3ce7ff0d09154ecd20